



[12] Patent

| | |
|---|---|
| [11] Patent No.: GC 0000108 | Number of the Decision to Grant the Patent: 5/335 |
| [45] Date of Publishing the Grant of the Patent: 29/06/2005 4/2005 | Date of the Decision to Grant the Patent: 03/04/2005 |
| [21] Application No.: GCC/P/1999/273 [22] Filing Date: 08/09/1999 [30] Priority: [31] Priority No. [32] Priority date [33] State 60/100927 17/09/1998 US [72] Inventors: 1- Michael Paul DeNinno, 2- George Tetteh Magnus-Aryitey, 3- Roger Benjamin Ruggeri, 4- Ronald Thure Wester [73] Owner: Pfizer Products Inc., Eastern Point Road, Groton, Connecticut 06340, USA [74] Agent: Nassir Ali Kadasa | [51] Int. Cl. ⁷ : C07D 215/42, 221/16, 215/46, 417/12, 413/12; A61K 31/47 [56] Cited Documents: - EP 0818448 A (BAYER AG) 14 January 1998 |

[54] 4-AMINO SUBSTITUTED-2-SUBSTITUTED-1, 2, 3, 4-TETRAHYDROQUINOLINES

[57] Abstract: Cholesteryl ester transfer protein inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.

No. of claims: 53